scholarly journals 142 Comparison of Volumetric Extent of Tumor Resection From a Prospective Multicenter Controlled Study of Fully Endoscopic versus Microscopic Transsphenoidal Surgery for Nonfunctioning Pituitary Adenomas: The TRANSSPHER Study

Neurosurgery ◽  
2018 ◽  
Vol 65 (CN_suppl_1) ◽  
pp. 95-95 ◽  
Author(s):  
Andrew S Little ◽  
Daniel F Kelly ◽  
William L White ◽  
Paul A Gardner ◽  
Juan C Fernandez-Miranda ◽  
...  
2020 ◽  
Vol 132 (4) ◽  
pp. 1043-1053 ◽  
Author(s):  
Andrew S. Little ◽  
Daniel F. Kelly ◽  
William L. White ◽  
Paul A. Gardner ◽  
Juan C. Fernandez-Miranda ◽  
...  

OBJECTIVEMany surgeons have adopted fully endoscopic over microscopic transsphenoidal surgery for nonfunctioning pituitary tumors, although no high-quality evidence demonstrates superior patient outcomes with endoscopic surgery. The goal of this analysis was to compare these techniques in a prospective multicenter controlled study.METHODSExtent of tumor resection was compared after endoscopic or microscopic transsphenoidal surgery in adults with nonfunctioning adenomas. The primary end point was gross-total tumor resection determined by postoperative MRI. Secondary end points included volumetric extent of tumor resection, pituitary hormone outcomes, and standard quality measures.RESULTSSeven pituitary centers and 15 surgeons participated in the study. Of the 530 patients screened, 260 were enrolled (82 who underwent microscopic procedures, 177 who underwent endoscopic procedures, and 1 who cancelled surgery) between February 2015 and June 2017. Surgeons who used the microscopic technique were more experienced than the surgeons who used the endoscopic technique in terms of years in practice and number of transsphenoidal surgeries performed (p < 0.001). Gross-total resection was achieved in 80.0% (60/75) of microscopic surgery patients and 83.7% (139/166) of endoscopic surgery patients (p = 0.47, OR 0.8, 95% CI 0.4–1.6). Volumetric extent of resection, length of stay, surgery-related deaths, and unplanned readmission rates were similar between groups (p > 0.2). New hormone deficiency was present at 6 months in 28.4% (19/67) of the microscopic surgery patients and 9.7% (14/145) of the endoscopic surgery patients (p < 0.001, OR 3.7, 95% CI 1.7–7.7). Microscopic surgery cases were significantly shorter in duration than endoscopic surgery cases (p < 0.001).CONCLUSIONSExperienced surgeons who performed microscopic surgery and less experienced surgeons who performed endoscopic surgery achieved similar extents of tumor resection and quality outcomes in patients with nonfunctioning pituitary adenomas. The endoscopic technique may be associated with lower rates of postoperative pituitary gland dysfunction. This study generally supports the transition to endoscopic pituitary surgery when the procedure is performed by proficient surgeons, although both techniques yield overall acceptable surgical outcomes.■ CLASSIFICATION OF EVIDENCE Type of question: therapeutic; study design: prospective cohort trial; evidence: class III.Clinical trial registration no.: NCT02357498 (clinicaltrials.gov)


2015 ◽  
Author(s):  
Dolores Moure ◽  
Javier Santamaria ◽  
Ihintza Larranaga ◽  
Pedro Gonzalez ◽  
Sara Valle ◽  
...  

2021 ◽  
Author(s):  
Jenie H. Hwang ◽  
Diane J. Aum ◽  
Michael R. Chicoine ◽  
Ralph G. Dacey ◽  
Joshua W. Osbun ◽  
...  

2017 ◽  
Vol 106 ◽  
pp. 315-321 ◽  
Author(s):  
Rares Chinezu ◽  
Franklin Fomekong ◽  
Héllène Lasolle ◽  
Jacqueline Trouillas ◽  
Alexandre Vasiljevic ◽  
...  

Author(s):  
J Han ◽  
AL Hebb ◽  
SA Imran ◽  
DB Clarke

Background: Post-operative delayed hormone dysfunction (DHD) in patients with nonfunctioning pituitary adenomas (NFPA) is highly variable and is predicted based on limited evidence. This study was undertaken to assess the likelihood of developing new DHD and its relation to the extent of tumor resection and recurrence. Methods: Four hundred fifty-five prospectively collected patient files were reviewed from our Program’s database. Inclusion criteria: NFPA; underwent surgery; and minimum follow-up of two years. Tumor recurrence was correlated with DHD (starting one year post-operatively) based on standardized annual imaging and hormone testing. Results: Eighty-nine patients met our inclusion criteria: 39 males and 50 females; mean follow-up was 4.3yrs (ranging from 2 to 11yrs). With no post-op residual tumor, the probability of developing DHD was only 7% by six years; no patient in this group developed DHD after three years of follow-up. In contrast, by six years, the probability of DHD was 33% in patients with residual stable tumor, and 54% in those with tumor recurrence/growth. Conclusions: By six years, approximately one third of patients with incomplete resection, and over half with tumor regrowth, will likely develop DHD. In contrast, the risk of DHD with complete tumor resection is <10% and, when seen, occurs within three years of surgery.


1994 ◽  
Vol 17 (9) ◽  
pp. 703-707 ◽  
Author(s):  
M. Marazuela ◽  
B. Astigarraga ◽  
A. Vicente ◽  
J. Estrada ◽  
C. Cuerda ◽  
...  

2018 ◽  
Vol 19 (2) ◽  
pp. 54-63
Author(s):  
Paulo Henrique Pires De Aguiar ◽  
Edward R. Laws Junior ◽  
Robert Dodd ◽  
Peter Hwang ◽  
Anne E. Getz

Microscopic transsphenoidal surgery is beyond any doubt a widely accepted and highly effective therapy for pituitary adenomas. Currently several centers have converted to an endoscopic transsphenoidal approach; suggesting that this technique provides more complete tumor resection, better visualization and reduce complications. However, there have been few series to document the results of this procedure. This report presents the technical details and compares it to the results of the microscopic method based on the experience of the group and a literature review. The endoscopic transnasal/ transsphenoidal technique is a safe and effective method for removal of pituitary adenomas. The results found in the literature suggest that the endoscope provides more complete tumor removal, and reduces complications. We believe that the advantages of the endoscopic technique will allow this procedure to become the future gold standard surgical therapy for pituitary adenomas.


Sign in / Sign up

Export Citation Format

Share Document